Novartis to sell Roche shares back for $20.7 billion
05-11-2021
photogearch / iStockphoto.com
Roche subsidiary Genentech received $209.5 million in unnecessary payments from Novartis Pharma for a patent licensing deal and is now refusing to return the payment, the Swiss pharma giant has alleged in a redacted complaint.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Genentech, US District Court for the Northern District of California, Chiron Corporation
